Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC. Deininger K, Raacke JN, Yousefzadeh-Nowshahr E, Kropf-Sanchen C, et al. Nuklearmedizin 2023 Sep 11. doi: 10.1055/a-2150-4130.

Read + Share

Amedeo Smart

Independent Medical Education

Deininger K, Raacke JN, Yousefzadeh-Nowshahr E, Kropf-Sanchen C, et al. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC. Nuklearmedizin 2023 Sep 11. doi: 10.1055/a-2150-4130.
PMID: 37696296